Arrien Pharmaceuticals signs license agreement for psoriasis treatment ARN-6039

Targeted therapeutics drug discovery and development company Arrien Pharmaceuticals has entered a worldwide license agreement with an unnamed US-based pharmaceutical firm for the clinical agent ARN-6039.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news